BMO cuts rating on Merck and Biogen, on lack of near term catalyst [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
perform" from "outperform," citing concerns over its Gardasil franchise in China and uncertainty around filling the revenue gap as Keytruda faces loss of exclusivity and biosimilar competition. The brokerage lowered its price target on Merck (NS:PROR) to $105 and flagged a lack of near-term catalysts, suggesting the stock may remain range-bound over the next year. BMO noted that the recent sell-off in Merck shares reflects growing skepticism in the pharmaceutical sector, with investors seeking more stable options. It added that while Merck has made progress in addressing post-2028 challenges, further clarity is needed to regain confidence. Additionally, brokerage also downgraded Biogen Inc (NASDAQ:BIIB) to "market perform" from "outperform," on slower-than-expected revenue growth for Alzheimer's drug Leqembi, erosion in its multiple sclerosis business, and weaker growth in its rare disease portfolio. The brokerage cut its price target for Biogen to $164, noting limited near-te
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- More on MRK's HIV-1 Program [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]Yahoo! Finance
- Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gain [Yahoo! Finance]Yahoo! Finance
- Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (NYSE: MRK) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating. They now have a $105.00 price target on the stock, down previously from $136.00.MarketBeat
MRK
Earnings
- 10/31/24 - Beat
MRK
Sec Filings
- 11/22/24 - Form 8-K
- 11/6/24 - Form 10-Q
- 11/4/24 - Form 25-NSE
- MRK's page on the SEC website